Correspondence 0001213900-25-022696 from Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd.
Date: March 11, 2025 · CIK: 0001611747 · Accession: 0001213900-25-022696
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285547
Letter
Scinai Immunotherapeutics Ltd.
Jerusalem BioPark, 2 nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
March 11, 2025
VIA EDGAR
United States Securities and Exchange Commission Division of Corporation Finance
Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549
Attention: Tim Buchmiller
Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS Scinai Immunotherapeutics Ltd. (CIK No. 0001611747) Registration Statement on Form F-1 (File No. 333-285547)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Scinai Immunotherapeutics Ltd. (the "Company") hereby requests acceleration of the effective date of its Registration Statement on Form F-1 (File No. 333-285547) so that it will be declared effective at 5:00 p.m., Eastern Standard Time, on March 12, 2025, or as soon thereafter as is practicable.
Should you have any questions regarding this letter, please do not hesitate to contact Perry Wildes, Adv., at +972 (3) 607-4444 or perry.wildes@goldfarb.com, of Goldfarb Gross Seligman & Co., counsel to the Company.
Sincerely,
Scinai Immunotherapeutics Ltd.
Show Raw Text
CORRESP 1 filename1.htm Scinai Immunotherapeutics Ltd. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel March 11, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS Scinai Immunotherapeutics Ltd. (CIK No. 0001611747) Registration Statement on Form F-1 (File No. 333-285547) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Scinai Immunotherapeutics Ltd. (the "Company") hereby requests acceleration of the effective date of its Registration Statement on Form F-1 (File No. 333-285547) so that it will be declared effective at 5:00 p.m., Eastern Standard Time, on March 12, 2025, or as soon thereafter as is practicable. Should you have any questions regarding this letter, please do not hesitate to contact Perry Wildes, Adv., at +972 (3) 607-4444 or perry.wildes@goldfarb.com, of Goldfarb Gross Seligman & Co., counsel to the Company. Sincerely, Scinai Immunotherapeutics Ltd. By: /s/ Amir Reichman Amir Reichman Chief Executive Officer